Outpatient management of diabetic ketoacidosis is inherently limited to early intervention during impending ketosis, as overt DKA with metabolic acidosis and volume depletion mandates emergency evaluation and inpatient intravenous resuscitation. In ambulatory patients with elevated capillary beta-hydroxybutyrate and hyperglycemia, home triage focuses on aggressive subcutaneous rapid-acting insulin administration, oral carbohydrate-electrolyte rehydration, and frequent ketone monitoring. However, persistent hyperketonemia exceeding 3.0 mmol/L, refractory nausea, vomiting, mental status alteration, or hemodynamic instability represent unequivocal failure of outpatient management requiring immediate transfer for intravenous insulin infusion, potassium repletion, and systemic acid-base correction.

Familial hyperaldosteronism type 2 is an autosomal dominant form of primary aldosteronism caused predominantly by gain-of-function mutations in the CLCN2 gene, which encodes the ClC-2 voltage-gated chloride channel. These mutations lead to increased channel opening, resulting in membrane depolarization of adrenal zona glomerulosa cells, activation of calcium signaling, and autonomous overproduction of aldosterone. Unlike type 1, this condition is non-suppressible with glucocorticoids and exhibits significant phenotypic overlap with sporadic primary aldosteronism, frequently presenting with early-onset hypertension, variable hypokalemia, and a high prevalence of aldosterone-producing adenomas. Diagnostic evaluation relies on demonstrating primary aldosteronism in multiple family members after excluding glucocorticoid-remediable aldosteronism, and clinical management centers on mineralocorticoid receptor antagonists or surgical adrenalectomy when unilateral adenomas are identified.

Phosphopenic disorders encompass conditions characterized by systemic phosphate wasting or deficiency, driven primarily by renal tubular defects, fibroblast growth factor 23 excess, or impaired gastrointestinal absorption. Key clinical manifestations include osteomalacia, rickets, muscle weakness, and profound fatigue. Diagnostic evaluation requires rigorous assessment of serum phosphate, fractional excretion of filtered phosphate, fibroblast growth factor 23 levels, and 1,25-dihydroxyvitamin D status. Management focuses on targeted etiology-specific therapy, incorporating phosphate supplementation combined with active vitamin D analogs to restore biochemical homeostasis and skeletal integrity while avoiding hypercalciuria and nephrocalcinosis.

Calcipenic osteomalacia presents with low-to-normal calcium, elevated PTH, hypophosphatemia, elevated alkaline phosphatase, and low urinary calcium. Evaluation requires ruling out pseudohypocalcemia and hypomagnesemia, followed by renal function assessment to distinguish renal osteodystrophy from calcipenic etiology. Paired vitamin D metabolite testing is critical: 25-hydroxyvitamin D assesses storage stores, while calcitriol identifies enzymatic defects (CYP27B1 in VDDR1A, CYP2R1 in VDDR1B) or end-organ resistance (VDDR2A). Non-responders require evaluation for malabsorption, hepatic CYP3A4 induction from antiepileptics, or isolated dietary calcium deficiency. Finally, full vitamin D repletion is necessary to unmask normocalcemic primary hyperparathyroidism, while isolated hypophosphatemia with suppressed calcitriol warrants evaluation for FGF23-mediated oncogenic osteomalacia.

Calcipenic osteomalacia arises primarily from vitamin D deficiency or resistance, or severe calcium malabsorption, resulting in impaired mineralization due to defective intestinal calcium transport and secondary hyperparathyroidism that accelerates bone resorption and hypophosphatemia. Phosphopenic osteomalacia stems from renal phosphate wasting, frequently driven by excess fibroblast growth factor 23 or hereditary tubular defects, which directly impairs hydroxyapatite crystal formation. Both entities manifest with bone pain, proximal muscle weakness, and pseudofractures, but precise differentiation via serum calcium, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, intact parathyroid hormone, and fibroblast growth factor 23 levels is essential to direct targeted replacement or mechanism-specific antineoplastic or biological therapies.

Clinical management of vitamin D deficiency requires distinguishing between native secosteroids and hydroxylated metabolites based on individual metabolic clearance and organ function. Cholecalciferol maintains superior pharmacokinetics over ergocalciferol due to higher hepatic CYP2R1 affinity, stronger vitamin D-binding protein avidity, and a longer half-life, resulting in more sustained serum 25-hydroxyvitamin D elevation. In patients with severe malabsorption, hepatic dysfunction, or acute deficiency, calcifediol offers direct intestinal absorption and rapid hepatic-independent repletion. Calcitriol and active analogs bypass renal CYP27B1 1-alpha-hydroxylation, making them strictly indicated for advanced chronic kidney disease, hypoparathyroidism, or specific metabolic bone disorders rather than nutritional deficiency.

Teprotumumab is a fully human monoclonal antibody targeting the insulin-like growth factor 1 receptor, revolutionizing the medical management of active thyroid eye disease. By blocking receptor signaling on orbital fibroblasts, it reduces inflammation, halts tissue expansion, and drives significant proptosis reduction and soft tissue improvement. Infused every three weeks for eight infusions, it offers an effective alternative to surgical decompression. Clinical monitoring must account for adverse effects, notably hyperglycemia and manageable hearing impairment.